Stock A205470 HUMASIS CO. LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Humasis Co. Ltd.

Equities

A205470

KR7205470008

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 13/05/2024 BST 		5-day change 1st Jan Change
1,928 KRW +0.10% Intraday chart for Humasis Co. Ltd. -0.52% +2.23%
03-18 Humasis Co. Ltd. announces an Equity Buyback for 17,533,607 shares. CI
03-18 Humasis Co. Ltd. authorizes a Buyback Plan. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization 1 39,160 324,844 571,042 456,449 239,924
Enterprise Value (EV) 1 32,012 313,748 376,093 140,601 -2,858
P/E ratio -31.6 x 14.8 x 3.78 x 2.55 x -4.33 x
Yield - - 1.2% - -
Capitalization / Revenue 4.28 x 7.11 x 1.77 x 0.97 x 17.4 x
EV / Revenue 3.5 x 6.86 x 1.17 x 0.3 x -0.21 x
EV / EBITDA -114 x 12 x 1.92 x 0.64 x 0.06 x
EV / FCF - -23,232,133 x 2,409,823 x 1,175,824 x 31,837 x
FCF Yield - -0% 0% 0% 0%
Price to Book 2.57 x 6.67 x 2.83 x 1.32 x 0.84 x
Nbr of stocks (in thousands) 112,692 136,776 136,776 128,126 127,213
Reference price 2 347.5 2,375 4,175 3,562 1,886
Announcement Date 17/03/21 17/03/21 25/02/22 09/03/23 15/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales 1 9,151 45,717 321,829 471,273 13,827
EBITDA 1 -280.2 26,117 195,576 219,569 -47,632
EBIT 1 -875.3 25,358 193,593 214,722 -52,355
Operating Margin -9.57% 55.47% 60.15% 45.56% -378.63%
Earnings before Tax (EBT) 1 -1,226 20,962 196,727 237,557 -62,180
Net income 1 -1,226 20,937 151,205 182,627 -55,424
Net margin -13.4% 45.8% 46.98% 38.75% -400.83%
EPS 2 -11.00 160.7 1,105 1,395 -435.5
Free Cash Flow - -13,505 156,066 119,577 -89,768
FCF margin - -29.54% 48.49% 25.37% -649.21%
FCF Conversion (EBITDA) - - 79.8% 54.46% -
FCF Conversion (Net income) - - 103.22% 65.48% -
Dividend per Share - - 50.00 - -
Announcement Date 17/03/21 17/03/21 25/02/22 09/03/23 15/03/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 - - - - -
Net Cash position 1 7,148 11,096 194,949 315,847 242,782
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - -13,505 156,066 119,577 -89,768
ROE (net income / shareholders' equity) - 65.5% 121% 66.6% -17.5%
ROA (Net income/ Total Assets) - 30.3% 59.2% 33.2% -8.03%
Assets 1 - 69,154 255,509 549,951 690,096
Book Value Per Share 2 135.0 356.0 1,477 2,706 2,259
Cash Flow per Share 2 33.70 105.0 1,291 153.0 96.70
Capex 1 2,987 15,081 18,061 44,510 22,204
Capex / Sales 32.64% 32.99% 5.61% 9.44% 160.58%
Announcement Date 17/03/21 17/03/21 25/02/22 09/03/23 15/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Diagnostic & Testing Substances

1st Jan change Capi.
HUMASIS CO. LTD. Stock Humasis Co. Ltd.
+2.23% 179M
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-1.52% 8.37B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+10.68% 5.84B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+26.76% 5.4B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-5.09% 4.37B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-50.75% 3.23B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+14.18% 2.8B
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+31.66% 2.26B
VITROLIFE AB Stock Vitrolife AB
-7.19% 2.22B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-1.69% 1.87B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. A205470 Stock
  4. Financials Humasis Co. Ltd.